UCI MIND faculty member and psychiatrist, David Sultzer, MD, has been awarded a $12 million dollar grant by the NIA to test a novel prevention treatment. He, along with two…
더 읽어보기
On February 17, 2023, a bipartisan group of Senators sent the Secretary of Health and Human Services, Javier Baccera, and the Administrator of the Centers for Medicare and Medicaid Services…
더 읽어보기
UCI MIND faculty member and Professor of Neurobiology and Behavior, Mathew Blurton-Jones Jones, PhD, has been awarded Early Career Innovator/Emerging Innovation of the Year by UCI Beall Applied Innovation. Read the…
더 읽어보기
Frontotemporal dementia (FTD) is a form of dementia that typically affects individuals in their 50s and 60s. It is therefore, commonly referred to as young onset dementia. Clinically, FTD can…
더 읽어보기
Irvine, Calif., Jan. 31, 2023 — Sustained support from philanthropists Joan and Don Beall to the the Institute for Memory Impairments and Neurological Disorders will allow for the continuation of…
더 읽어보기
UCI School of Medicine highlighted innovative research performed in the lab of Xiangmin Xu, PhD, UCI MIND faculty member and professor and Chancellor’s Fellow of anatomy and neurobiology in the…
더 읽어보기
In a somewhat surprising move, the US Food and Drug Administration (FDA) has declined to grant accelerated approval to Eli Lilly’s donanemab Read the full press release from Eli Lilly…
더 읽어보기
The recent FDA approval of lecanemab has generated a lot of buzz in recent days and UCI MIND director, Joshua Grill, PhD has been asked to comment in various highly…
더 읽어보기
UCI MIND faculty member and professor, Mathew Blurton-Jones, PhD, is featured in AlzForum for his lab’s recent collaborative work on creating a new strain of resistant microglia. Lead author and…
더 읽어보기
The post FDA grants accelerated approval to lecanemab appeared first on UCI MIND.
더 읽어보기